TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Nebulized Adrenalin and Oral Betamethasone in Children With Bronchiolitis Attending Pediatric Emergencies.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infants aged 6 weeks to 12 months admitted in paediatric emergency~* First episode of acute bronchiolitis defined as: expiratory dyspnea with breath slowing and/or sibilants and/or crackles preceded by (or associated with) a nasopharyngitis more or less febrile~* Respiratory distress assessment index score (RDAI) of 4 to 15 after a nasopharyngeal clearance~* Agreement of at least one of the parents for his child to participate in biomedical research~* Affiliation to social security (beneficiary or entitled), except beneficiary of State medical help~Exclusion Criteria:~* Prematurity (less than 37 weeks of gestation)~* Antecedent of invasive respiratory ventilation during neonatal period~* Antecedent of lung or chronic cardiac pathology of wich rhythm disorder, acute obstructive cardiomyopathy and coronary insufficiency~* Immune deficiency~* Active viral infection (hepatitis, zona, herpes, varicella, HIV)~* Proven or suspected tuberculosis~* Exposure to varicella during 15 days before inclusion~* Severe distress (defined as one of following signs: a pulse rate \>200/min, respiratory rate \>80/min, RDAI score \>15, neurological disorders)~* Nebulization (aerosol spray) of Salbutamol or other bronchodilator treatment during the 24 hours before the inclusion~* Inhalation (spray) of Salbutamol during the preceding 24 hours~* Oral or inhaled corticosteroids during the preceding 2 weeks~* Previous episode of wheezing or ascertained diagnosis of asthma~* Hypersensitivity to one of the constituting of oral betamethasone~* Vaccination by living vaccine during the preceding 2 weeks

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 12 Months
- Healthy Volunteers: f

Study Arms:
- 0.9% saline solution - oral betamethasone placebo (Type: PLACEBO_COMPARATOR): Control arm: 0.9% saline solution - oral betamethasone placebo
- adrenaline - oral betamethasone (Type: EXPERIMENTAL): Experimental arm : adrenaline and betamethasone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Angiotensin Receptors and Age Related Mitochondrial Decline in HIV Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* able to provide informed consent~* able to attend an extended (\~4 hour) Clinical Research Visit~* documented HIV seropositivity~* on a stable anti-retroviral therapy (ART) regimen for at least 12 months~* HIV plasma viral load \< 50 copies/ml for at least 6 months~* Systolic blood pressure \>110~Exclusion Criteria:~* creatinine \> 1.5 ULN (or creatinine clearance \< 60 ml/min)~* anti-hypertensive therapy with ACE-I or AT1R-blockers~* inability to perform functional measures (e.g. non-ambulatory without assistance, requires a prosthesis)~* recent (within 30 days) acute illness requiring medical therapy or hospitalization~* immunosuppressive agents (e.g. \> 20 mg/d x 2 or more weeks of prednisone or equivalent, chemotherapy) in the last 6 months~* cancer requiring treatment w/in 3 yrs (except for non-melanoma skin cancer)~* blood thinning medications such as Coumadin or Plavix or a bleeding disorder such as hemophilia that could cause complications during muscle biopsies~* pregnancy (will provide urine test for females of child bearing potential)~* regular use of non-steroidal anti-inflammatory drugs or other immune modulating agents.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Placebo control (Type: PLACEBO_COMPARATOR): 20 HIV-infected participants will be randomized into a blinded arm where they will receive 24 weeks of placebo therapy. During this time, they will undergo the same study procedures as the intervention arm.
- Valsartan (Type: EXPERIMENTAL): 20 HIV-infected participants will be randomized into a blinded arm where they receive 24 weeks of valsartan therapy. For those subjects randomized to the valsartan group, they will receive valsartan 40 mg by mouth daily for 2 weeks, then increase to 80 mg by mouth daily for the remaining 22 weeks. During this time, they will undergo the same study procedures as the placebo arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of RAD001 + TACE in Localized Unresectable HCC

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed hepatocellular carcinoma limited to liver and not suitable for resection, liver transplant, or radiofrequency ablation.~* Intermediate stage (stage B) (according to recognized guidelines) and suitable for TACE therapy~* At least one nodule between \> 2cm and ≤ 15cm in diameter with no vascular invasion or abdominal lymph node or distant metastases.~* Must have 1 tumor which can be measured in 1 dimension according to specified criteria (RECIST and mRECIST) and has not previously been treated with any type of therapy.~* ECOG performance status \< 2cm~* Cirrhotic status of Child-Pugh class A or early B~* HBV-DNA or HBsAg positive at screen or baseline: preventative treatment with anti-viral started 1-2 weeks prior to receiving study drug~Exclusion Criteria:~* Any local and/or investigational drugs within 28 days prior to randomization~* Active bleeding during the last 28 days prior to screening including variceal bleeding~* Prior therapy with mTOR inhibitors~* Tumor burden of \> 60% liver involvement~* Prior systemic or local therapy including TACE except for the first TACE at Day 0), surgery or liver transplantation~* Failed first TACE at Day 0, Cycle 1 for any reason~* Known history of human immunodeficiency virus (HIV) seropositivity (HIV testing is not mandatory)~* Alcohol intake of 80 grams per day~* Undergone major surgery ≤ 3 weeks prior to starting study drug or who have not recovered from surgery~* Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- everolimus + TACE (Type: EXPERIMENTAL): everolimus 7.5mg/day by mouth + transcatheter arterial chemoembolization (TACE)
- placebo + TACE (Type: PLACEBO_COMPARATOR): Placebo by mouth + transcatheter arterial chemoembolization (TACE)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Botox in Obstructed Defecation Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females 18 years or older of all races and backgrounds~* Competent to give informed consent~* Meet the Rome III diagnostic criteria for functional constipation~* Inability to relax the puborectalis muscle at electromyography~* Altomare Obstructed Defecation Syndrome score of 15 points or above~* Failure of treatment with 2 conservative measures which may be as follows:~  * 1 laxative (osmotic or stimulant) for 2 weeks~ * 1 fiber supplement for one month~ * And/or trial of biofeedback for at least 4 sessions~Exclusion Criteria:~* Previous treatment with Botox (possible antibodies)~* Known hypersensitivity to any of the components of the toxin~* Medication regimen includes narcotics~* Previous radiation therapy to the anal canal and rectum~* Prior proctectomy~* Presence of unhealed and symptomatic anal fissure~* Presence of anal pain~* Presence of fecal incontinence~* Presence of full thickness rectal prolapse~* Presence of internal sphincter myopathy~* Inflammatory bowel disease or proctitis~* Pregnancy or breast-feeding~* Subject is currently enrolled/ just finished participating in a clinical trial in which the intervention/ its carry-over effect may interact with the intervention in this trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Botulinum Toxin-A (Type: ACTIVE_COMPARATOR): Patients will receive Botulinum Toxin-A (Botox) injected in the puborectalis muscle and external anal sphincter. We will use 100 units of Botox, a dose with a good safety profile that has been proven to work in previous studies performed in adults.
- Normal saline (Type: PLACEBO_COMPARATOR): Patients will receive normal saline (placebo) injected in the puborectalis muscle and external anal sphincter.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Role of Non-Alcoholic Fatty Liver Disease in Gestational Diabetes

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* a pregnant female~* age between 18-50 years.~Exclusion Criteria:~* pregravid diabetes mellitus~* inability to understand and speak English~* inability to provide consent~* plans to relocate out of the area within 12 months postpartum

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Subjects with Gestational Diabetes (Type: None): Subjects with a history of Gestational Diabetes will provide blood samples, blood pressure measured with a blood pressure cuff, pulse, height, weight, and ultrasound of the liver at the 6 week postpartum and 6 month postpartum visits.
- Controls without Gestational Diabetes (Type: None): Matched control subjects without Gestational Diabetes will provide blood samples, blood pressure measured with a blood pressure cuff, pulse, height, weight, and ultrasound of the liver at the 6 week postpartum and 6 month postpartum visits.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Detecting Early Onset Pre-eclampsia and Use of Placental Growth Factor (PlGF) for Marker of Trisomy 21

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Singleton pregnancy~* Nulliparous pregnancy~* Gestation age between 6.0-13.6 weeks by last menstrual period verified by ultrasound~* Blood sample provided at gestational age 6.0-13.6 weeks~* Informed Consent~Exclusion Criteria:~* Multi-fetal pregnancy~* Primiparous or multiparous pregnancy~* Mental retardation or other mental disorders that impose doubts regarding the true patient's willingness to participate in the study~* Gestation age below 6.0 or above 13.6 weeks by last menstrual period verified by ultrasound.~* Lack of blood sample at the specified enrollment period~* Known major fetal anomaly or fetal demise~* Lack of demographic data

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- study group (Type: None): patients coming to clinique OVO in the 1st trimester of pregnancy to undergo prenatal screening

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Study of Respiratory Gated Proton Beam Radiotherapy for Inoperable Pancreas Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Pathologically confirmed adenocarcinoma of the pancreas or a serum CA19-9 level higher than normal limits and an pancreas cancer-compatible radiological features in one or more in CT/MRI/PET scans~* Unresectable disease base on institutional standard criteria of unresectability or recurrent disease following radical surgery. There is no evidence of metastatic disease in the major viscera and no peritoneal seeding~* Patients with biliary or gastroduodenal obstruction must have drainage prior to starting chemoradiation~* All malignant disease must be encompassable within a single irradiation field (15x15cm maximum)~* All patients must have radiographically assessable disease~* No previous irradiation to the planned field~* Age of ≥ 18 years~* Performance status of 0 to 2 on the Eastern Cooperative Oncology Group (ECOG) score~* Required Entry Labortory Parameters:~  * WBC count ≥ 2,000/mm3~ * hemoglobin level ≥ 7.5 g/dL~ * platelet count ≥ 100,000/mm3~ * total bilirubin ≤ 2.0 mg/dL (Patients with elevated bilirubin due to obstruction should be stented and their bilirubin should be decreased ≤ 2.0 mg/dL prior to study entry)~ * creatinine ≤ 3.0 mg/dL~* Oral intake (including J-tube feeding) of ≥ 1,500 calories/day should be maintained.~Exclusion Criteria:~* There is evidence of metastasis in the major viscera or peritoneal seeding.~* Age of \< 18 years~* Previous history of RT adjacent to planned field~* Poor performance status of 3 to 4 on the Eastern Cooperative Oncology Group (ECOG) score~* Pregnant or breast feeding status~* Previous history uncontrolled other malignancies within 2 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Craniomaxillofacial Allotransplantation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Signed and dated all required IRB approved consent forms~* Male or female recipient between the ages of 18-64 years. \* Recipients do not need to be same gender as donor\*~* Facial composite tissue defect requiring facial transplantation as determined by the treating Plastic and Reconstructive Surgeon. Inclusive facial functional subunit tissue loss. Including but not limited to irreparable peri-oral, peri-orbital, and peri-nasal damage.~* Patient has been encouraged to seek a second opinion from a Plastic Surgeon with specialized focus in facial reconstruction.~* Willingness to participate in ongoing psychiatric, psychological and social work evaluations prior to and post-transplant surgery~* The subject is able to complete pre-transplant examination and screening procedures.~* Patient has been approved by Patient Selection Committee for placement on the recipient waiting list~* The subject is willing to continue immunosuppression regimen as directed by treating physician.~* Subject is willing and able to return to follow-up visits as described in treatment plan.~* Subjects must have autogenous tissue options available for reconstruction in event of graft failure.~* Normal GFR (glomerular filtration rate) \>60~* Negative pregnancy test within 48hrs of transplant for women of childbearing age and who agree to use a reliable form of contraception for one year following transplant.~Exclusion criteria:~* Subject has an uncontrolled infection~* Serious co-morbidities~* Positive serology for HIV; Hepatitis B/C Antigen~* Active malignancy within 5 years with the exclusion of non-melanoma~* Subject has active substance abuse/ alcoholism~* Active Severe Psychiatric Illness~* Cognitive limitations affecting the patient's ability to provide informed consent~* Recent history of medical nonadherence~* Unstable social situation as evidence by lack of stable housing and/or lack of a supportive significant other.~* Recent history of medical non-adherence.~* Lack of stable housing and/or supportive significant other/caregiver throughout all phases of the study~* Currently active smoker within 1 year~* Subjects with any cognitive deficits related to a TBI (traumatic brain injury) and or any organic neurological disorders will not be considered for this protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Face Transplant recipient (Type: EXPERIMENTAL): Single Arm study, all participants will receive Craniomaxillofacial allotransplantation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Follow-up of Elderly Patients Undergoing Instrumented Lumbar Arthrodesis Supplemented by the Implanet Jazz System(TM)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients who are candidates for single, two- or three-level spinal arthrodesis surgery supplemented by the Implanet Jazz System~* Patients at least 60 years of age.~Exclusion Criteria:~* Patients under the age of 60 years old are excluded.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Single Cohort (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Effect of Serelaxin on High-sensitivity Cardiac Troponin I (Hs-cTnI) Release in Patients With Chronic Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Male or female ≥ 18 years of age, with body weight ≤ 160 Kg~* Diagnosis of stable CHF:~  * New York Heart Association (NYHA) functional Class II/III.~ * Receiving guideline-recommended treatment for CHF.~* Left ventricular ejection fraction \< 45%, obtained within the last 3 months prior to screening.~* NT-proBNP \> 300 ng/L in sinus rhythm or \> 900 ng/L if not in sinus rhythm (determined locally).~* Ability to exercise for at least 10 to 12 minutes based on investigator's judgment.~* Systolic BP ≥ 125 mmHg at randomization~* Renal function defined as an eGFR of ≥ 25 mL/min/1.73 m\^2 at screening (sMDRD formula).~Key Exclusion Criteria:~* Dyspnea primarily due to non-cardiac causes.~* Increased risk of developing hypotension during vasodilator therapy according to investigators judgement.~* Any contraindication for exercise testing and spirometry.~* Stopping of the spiroergometry at screening according to the stopping rules, unless the patient has reached maximum exercise capacity defined as carbon dioxide production/oxygen consumption (VCO2/VO2) \> 1.05.~* Change in guideline-recommended CHF treatment within 1 month prior to screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Serelaxin followed by Placebo (Type: EXPERIMENTAL): On Day 1 of treatment period 1, Serelaxin will be administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen The routine exercise assessment will commence at minute 120. In treatment period 2, on day 15 ± 1-day washout, matching placebo will be administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen.
- Placebo followed by Serelaxin (Type: EXPERIMENTAL): On Day 1 of treatment period 1, matching placebo will be administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen The routine exercise assessment will commence at minute 120. In treatment period 2, on day 15 ± 1-day washout, Serelaxin will be administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of ACT and Float REST on Burnout Syndrome.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
None

- Gender: None
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Acceptance and Commitment Therapy (ACT) (Type: ACTIVE_COMPARATOR): None
- Float REST (Type: ACTIVE_COMPARATOR): None
- ACT + Float REST (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval